Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

PURPOSE: This study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation–associated breast cancer. PATIENTS AND METHODS: This single-arm phase II study enrolled patients wit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Telli, Melinda L., Jensen, Kristin C., Vinayak, Shaveta, Kurian, Allison W., Lipson, Jafi A., Flaherty, Patrick J., Timms, Kirsten, Abkevich, Victor, Schackmann, Elizabeth A., Wapnir, Irene L., Carlson, Robert W., Chang, Pei-Jen, Sparano, Joseph A., Head, Bobbie, Goldstein, Lori J., Haley, Barbara, Dakhil, Shaker R., Reid, Julia E., Hartman, Anne-Renee, Manola, Judith, Ford, James M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2015
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451172/
https://ncbi.nlm.nih.gov/pubmed/25847929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.0085
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky